全文获取类型
收费全文 | 1418661篇 |
免费 | 103406篇 |
国内免费 | 1904篇 |
专业分类
耳鼻咽喉 | 19312篇 |
儿科学 | 46854篇 |
妇产科学 | 39111篇 |
基础医学 | 210952篇 |
口腔科学 | 39283篇 |
临床医学 | 129932篇 |
内科学 | 275097篇 |
皮肤病学 | 31850篇 |
神经病学 | 116429篇 |
特种医学 | 54981篇 |
外国民族医学 | 288篇 |
外科学 | 205169篇 |
综合类 | 26866篇 |
现状与发展 | 1篇 |
一般理论 | 609篇 |
预防医学 | 112075篇 |
眼科学 | 32282篇 |
药学 | 103504篇 |
6篇 | |
中国医学 | 2295篇 |
肿瘤学 | 77075篇 |
出版年
2019年 | 11377篇 |
2018年 | 16610篇 |
2017年 | 12860篇 |
2016年 | 14731篇 |
2015年 | 16867篇 |
2014年 | 21943篇 |
2013年 | 33100篇 |
2012年 | 46362篇 |
2011年 | 48317篇 |
2010年 | 27828篇 |
2009年 | 26094篇 |
2008年 | 45686篇 |
2007年 | 49186篇 |
2006年 | 48693篇 |
2005年 | 48101篇 |
2004年 | 46048篇 |
2003年 | 44233篇 |
2002年 | 43021篇 |
2001年 | 61101篇 |
2000年 | 62111篇 |
1999年 | 52370篇 |
1998年 | 13905篇 |
1997年 | 12507篇 |
1996年 | 12606篇 |
1995年 | 12567篇 |
1994年 | 11729篇 |
1993年 | 10968篇 |
1992年 | 40150篇 |
1991年 | 39666篇 |
1990年 | 38342篇 |
1989年 | 37089篇 |
1988年 | 34276篇 |
1987年 | 33608篇 |
1986年 | 32005篇 |
1985年 | 30239篇 |
1984年 | 23031篇 |
1983年 | 20041篇 |
1982年 | 11928篇 |
1979年 | 22060篇 |
1978年 | 16237篇 |
1977年 | 13468篇 |
1976年 | 12433篇 |
1975年 | 13729篇 |
1974年 | 16539篇 |
1973年 | 16230篇 |
1972年 | 15442篇 |
1971年 | 14410篇 |
1970年 | 13559篇 |
1969年 | 12786篇 |
1968年 | 11960篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Clinical Oral Investigations - To evaluate the effect of membrane occlusiveness and experimental diabetes on early and late healing following guided bone regeneration. A total of 30 Wistar rats... 相似文献
3.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
4.
5.
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways 下载免费PDF全文
Ahmed A Abd-Rabou Hanaa H Ahmed Safaa H MohamedSoheir E KotobMohamed S Kishta 《Asian Pacific journal of cancer prevention》2022,23(12):4261-4273
Objective: Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo. Methods: The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways. Results: The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation. Conclusion: The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment. 相似文献
6.
Osama Y Safdar Rana M Baghdadi Sereen A Alahmadi Bana E Fakieh Amaal M Algaydi 《World Journal of Clinical Pediatrics》2022,11(1):14-26
Whether the underlying mutations are homozygous, heterozygous, or co-inherited with other hemoglobinopathies, sickle cell disease is known to afflict the kidneys, leading to the clinical entity known as sickle cell nephropathy (SCN). Although common, SCN remains diagnostically elusive. Conventional studies performed in the context of renal disorders often fail to detect early stage SCN. This makes the quest for early diagnosis and treatment more challenging, and it increases the burden of chronic kidney disease-related morbidity among patients. Novel diagnostic tools have been employed to overcome this limitation. In this study, we discuss various biomarkers of SCN, including those employed in clinical practice and others recently identified in experimental settings, such as markers of vascular injury, endothelial dysfunction, tubulo-glomerular damage, and oxidative stress. These include kidney injury molecule-1, monocyte chemoattractant protein-1, N-acetyl-B-D-glucosaminidase, ceruloplasmin, orosomucoid, nephrin, and cation channels, among others. Furthermore, we explore the potential of novel biomarkers for refining diagnostic and therapeutic approaches and describe some obstacles that still need to be overcome. We highlight the importance of a collaborative approach to standardize the use of promising new biomarkers. Finally, we outline the limitations of conventional markers of renal damage as extensions of the pathogenic process occurring at the level of the organ and its functional subunits, with a discussion of the expected pattern of clinical and biochemical progression among patients with SCN. 相似文献
7.
8.
9.
Andreas Lundin Martin Annborn Ola Borgquist Joachim Düring Johan Undén Christian Rylander 《Acta anaesthesiologica Scandinavica》2023,67(5):655-662
Patients admitted to intensive care after cardiac arrest are at risk of circulatory shock and early mortality due to cardiovascular failure. The aim of this study was to evaluate the ability of the veno-arterial pCO2 difference (∆pCO2; central venous CO2 – arterial CO2) and lactate to predict early mortality in postcardiac arrest patients. This was a pre-planned prospective observational sub-study of the target temperature management 2 trial. The sub-study patients were included at five Swedish sites. Repeated measurements of ∆pCO2 and lactate were conducted at 4, 8, 12, 16, 24, 48, and 72 h after randomization. We assessed the association between each marker and 96-h mortality and their prognostic value for 96-h mortality. One hundred sixty-three patients were included in the analysis. Mortality at 96 h was 17%. During the initial 24 h, there was no difference in ∆pCO2 levels between 96-h survivors and non-survivors. ∆pCO2 measured at 4 h was associated with an increased risk of death within 96 h (adjusted odds ratio: 1.15; 95% confidence interval [CI]: 1.02–1.29; p = .018). Lactate levels were associated with poor outcome over multiple measurements. The area under the receiving operating curve to predict death within 96 h was 0.59 (95% CI: 0.48–0.74) and 0.82 (95% CI: 0.72–0.92) for ∆pCO2 and lactate, respectively. Our results do not support the use of ∆pCO2 to identify patients with early mortality in the postresuscitation phase. In contrast, non-survivors demonstrated higher lactate levels in the initial phase and lactate identified patients with early mortality with moderate accuracy. 相似文献